Summary of Anke Bio's Conference Call Company Overview - Anke Bio focuses on biopharmaceuticals, with a strategic emphasis on traditional Chinese medicine and precision medicine, actively expanding into mRNA, ADC viruses, and cell therapy fields, particularly in the Yangtze River Delta region [2][4][31] Core Products and Development Focus - Main products include growth hormones and interferons for growth development and antiviral applications, with antibody drugs like Trastuzumab approved for market [2][5] - The company is investing heavily in biopharmaceuticals as a key growth driver, with traditional Chinese medicine as a secondary profit source, and focusing on peptides, small molecules, and cell immunotherapy to support performance growth [2][5][31] Research and Development Investment - Over the past seven years, Anke Bio has invested approximately 200 million yuan annually in R&D, accounting for about 10% of revenue, indicating a strong commitment to innovative drug development [7][8] Key R&D Areas - R&D strategy focuses on growth development, reproductive assistance, antiviral and anti-infection fields, and cancer treatment through antibodies, mRNA, CAR-T, and viral therapies [8][9] - Specific projects include in vivo CAR-T technology and mRNA platform development, with clinical trial approvals for HPV, RCV, and COVID-19 [12][13] Clinical Stage Products - Important clinical stage products include HU21 (E9), AK2017 (GHFC), AK1,008, and AK1,012, expected to enter phase III clinical trials by the end of 2025 [3][14][15] - The company plans to utilize all resources to ensure the progress of these products and expedite their market approval [15] Collaborations and Partnerships - Anke Bio is engaged in multiple collaborations, including with Baoyi for the domestic launch of the first long-acting FSH and with Weisen for long-acting growth hormone development [3][31][32] - The company has established partnerships with various academic institutions and companies to enhance its R&D capabilities and product offerings [12][29] Market Potential and Future Plans - The long-acting FSH product is expected to capture a significant market share due to its convenience over short-acting alternatives, with an estimated annual market of 1 million cycles [32] - Anke Bio aims to transition from a focus on generic drugs to innovative drug development, particularly in oncology, autoimmune diseases, cell therapy, and mRNA drugs [34] Additional Insights - The company has a highly qualified R&D team, with 40.64% holding master's degrees or higher, indicating a strong foundation for innovation [11] - Anke Bio's dual-antibody product is currently in phase I clinical trials, with plans to advance to phase II and III based on positive results [24] This summary encapsulates the key points from Anke Bio's conference call, highlighting its strategic focus, product pipeline, R&D investments, and future growth plans.

法律意见书 安徽天禾律师事务所 关于 安徽安科生物工程（集团）股份有限公司 第 4 期员工持股计划（草案） 之 法律意见书 法律意见书 安徽天禾律师事务所 关于安徽安科生物工程（集团）股份有限公司 第 4 期员工持股计划（草案） 之法律意见书 致：安徽安科生物工程（集团）股份有限公司 安徽天禾律师事务所接受安徽安科生物工程（集团）股份有限公司（下称 "安科生物"或"公司"）的委托，指派王炜、朱华耀律师（下称"本所律师"） 担任安科生物拟实施第 4 期员工持股计划（以下简称"员工持股计划"）的专 项法律顾问，根据《中华人民共和国证券法》（以下简称《证券法》）、《中 华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会（以 下简称"中国证监会"）《关于上市公司实施员工持股计划试点的指导意见》 （以下简称《试点指导意见》）、《深圳证券交易所创业板上市公司自律监管 指引第 2 号——创业板上市公司规范运作》（以下简称《自律监管指引第 2 号》）等法律、行政法规、规范性文件和中国证监会的有关规定，就安科生物 第 4 期员工持股计划的相关事项出具本法律意见书。 为出具本法律意见书，本所律师谨作如下声明： 一 ...

Core Viewpoint - The strategic cooperation between Weisheng Pharmaceutical and Anke Bio aims to promote the long-acting growth hormone product, Longpei Growth Hormone, in the Chinese market, leveraging Anke's extensive experience and sales network in the biopharmaceutical sector [1][2]. Group 1: Partnership Details - Weisheng Pharmaceutical has signed a strategic cooperation framework agreement with Anke Bio, granting Anke exclusive promotion rights for Longpei Growth Hormone in specific regions of China [1]. - The collaboration will focus on the commercialization of Longpei Growth Hormone and explore broader cooperation on other target products, including localized production and marketing [1]. - Anke Bio has over 30 years of experience in biopharmaceuticals and a well-established sales network, which will facilitate Weisheng's market entry [1]. Group 2: Product Information - Longpei Growth Hormone is a new long-acting growth hormone designed to treat pediatric growth hormone deficiency (PGHD) and is expected to provide new treatment options for affected children [1]. - The product has already been approved for sale in the United States and Europe, with expectations for approval in China by 2025 and plans for localized commercial production by 2028 [1]. Group 3: Strategic Importance - Anke Bio's chairman highlighted that the collaboration will enhance their commercial layout in the pediatric growth field and redefine the growth hormone market [2]. - Weisheng's CEO emphasized the synergy between their innovative research and Anke's established sales channels, aiming to accelerate the product's market introduction and benefit a wide patient population [2].

目前，中国儿童生长发育治疗市场潜力巨大，但同时竞争亦非常激烈，优质产品的商业化效率直接影响 市场占有率。此次合作中，安科生物将充分依托现有渠道资源，精准向医生与患者传递隆培促生长素 的"长效、便捷"产品优势，有效缩短市场教育周期，加速产品在中国市场的渗透与放量。同时，该合作 将补齐安科生物在长效生长激素方面的短板，实现"短效水剂+粉剂+长效"的全剂型覆盖，提升安科生 物在儿童生长发育领域的综合竞争力。 今日（7月14日），安科生物（股票代码：300009.SZ）与维昇药业（股票代码：02561.HK）签订战略 合作框架协议，安科生物将在中国境内特定区域内，以排他性独家推广的方式，负责隆培促生长素产品 的市场推广工作。此外，双方同意，在其他目标产品上进行更为广泛且深入的合作探讨，涵盖本地化生 产、商业化推广合作等多个层面。 安科生物董事长宋礼华表示："近日，公司刚刚与上海宝济药业达成了长效促卵泡激素（FSH-CTP）中 国区独家代理协议。此次与维昇药业合作，是公司'研发+渠道'战略的又一重要里程碑。未来，我们将 以隆培促生长素为起点，与维昇药业在更多领域探索创新合作模式，共同为推动中国生物医药产业的高 质量发展 ...

Group 1 - The company has developed the draft of the 4th employee stock ownership plan in compliance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][2] - The board confirms that the implementation of the employee stock ownership plan does not harm the interests of the company and all shareholders, and there are no forced participation scenarios [1][2] - The eligibility criteria for participants in the employee stock ownership plan meet the requirements set forth in the relevant regulations, ensuring the legality and validity of the participants' qualifications [1]

Core Viewpoint - The company has established the 4th Employee Stock Ownership Plan (ESOP) to enhance employee engagement, attract talent, and align the interests of employees, shareholders, and the company for long-term development [1][2][3]. Summary by Sections General Principles - The ESOP aims to motivate participants, create a shared interest between employees and shareholders, and improve corporate governance [2][3]. - The plan adheres to legal compliance, voluntary participation, risk-bearing by participants, and selective involvement of employees [2][3]. Plan Structure - The total number of shares under the ESOP is capped at 2.894406 million shares, representing 1% of the company's total shares for any single participant [4][5]. - The plan is limited to key personnel in the oncology division, excluding directors, supervisors, and senior management [4][5]. Funding and Stock Source - Funding for the ESOP comes from employees' legal salaries and self-raised funds, with no financial assistance from the company [5][6]. - Shares for the ESOP will be sourced from the company's repurchased shares, with a maximum of 2.894406 million shares available for transfer [5][6]. Pricing and Incentives - The purchase price for the shares is set at 4.38 yuan per share, based on a calculated method considering market conditions [7][8]. - The pricing strategy aims to encourage employee participation while ensuring alignment with company performance and shareholder interests [7][8]. Duration and Lock-up Period - The ESOP has a duration of 72 months, with a lock-up period of 12 months before shares can be gradually unlocked [8][9]. - The unlocking schedule allows for 20% of shares to be released at specified intervals, promoting long-term commitment from participants [8][9]. Management and Governance - The ESOP is managed by a committee elected by participants, ensuring that the interests of all stakeholders are represented [12][15]. - The board of directors is responsible for drafting and modifying the ESOP, with oversight from the supervisory board [12][15]. Rights and Obligations of Participants - Participants must pay their subscription fees on time and are subject to performance evaluations that affect their share unlocks [13][19]. - Participants are prohibited from transferring or using their shares as collateral without committee approval [19][20]. Distribution of Benefits - Cash dividends received during the lock-up period will be retained within the ESOP and distributed proportionally after the lock-up ends [23][24]. - Upon the expiration of the ESOP, a final settlement will be conducted within 30 working days, distributing shares based on participants' holdings [24][26].

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 第 4 期员工持股计划管理办法 二〇二五年七月 第一章 总则 第一条 为规范安徽安科生物工程（集团）股份有限公司（以下简称"公司"） 第 4 期员工持股计划（以下简称"员工持股计划"或"本持股计划"）的实施， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》 （以下简称"《证券法》"）、《关于上市公司实施员工持股计划试点 的指导意见》 （以下简称"《指导意见》"）、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》（ 以下简称"《自律监管指引第 2 号》"）等相关法律法规、规范性文件和《公司章程》的规定，特制定《安徽 安科生物工程（集团）股份有限公司第 4 期员工持股计划管理办法》（以下简称 "《管理办法》"或"本管理办法"）。 第二章 员工持股计划的制定 第二条 员工持股计划的目的 公司根据《公司法》、《证券法》、《指导意见》、《自律监管指引第 2 号》及其 他有关法律、法规和规范性文件以及《公司章程》的有关规定制定本持股计划草 案。员工持股计划的目的在于： 一、充分 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-037 安徽安科生物工程（集团）股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2025 年第二次临时股东大会 2、会议召集人：公司董事会 3、公司第八届董事会第二十次会议审议通过了《关于召开 2025 年第二次临时股 东大会的议案》，本次股东大会会议的召开符合有关法律、行政法规、部门规章、规 范性文件和公司章程的规定。 4、召开方式：本次股东大会采取现场表决与网络投票相结合的方式召开。 （1）现场投票：股东本人出席现场会议或通过授权委托他人出席现场会议； （2）网络投票：本次股东大会将通过深圳证券交易所交易系统和互联网投票系 统向公司股东提供网络形式的投票平台，公司股东可以在上述网络投票时间内通过上 述系统行使表决权。 公司股东只能选择现场投票和网络投票中的一种表决方式，表决结果以第一次有 效投票结果为准。 5、会议召开日期和时间 现场会议召开日期、时间：2025 年 7 月 28 日（星期一）上 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-036 根据《公司法》《证券法》《关于上市公司实施员工持股计划试点的指导意见》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等法律法规、规章及规范性文件的规定，监事会全体监事对公司第 4 期员工持股 计划相关事项进行核查后发表意见，认为公司实施第 4 期持股计划符合公司长远 发展的需要，不存在损害公司及全体股东利益的情形。本议案尚需提交公司 2025 年第二次临时股东大会审议。 具体内容详见同日披露于中国证监会指定创业板信息披露网站巨潮资讯网 （www.cninfo.com.cn）的相关公告。 二、以 3 票赞成，0 票反对，0 票弃权审议通过《关于公司<第 4 期员工持 股计划管理办法>的议案》 为保证公司员工持股计划的顺利进行，规范员工持股计划的实施，保障公司 员工的利益和权益，根据《公司法》《证券法》《关于上市公司实施员工持股计划 安徽安科生物工程（集团）股份有限公司 关于第八届监事会第十八次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科 ...

3、公司审议第 4 期员工持股计划相关议案的决策程序合法、有效，不存在 损害公司及全体股东利益的情形，亦不存在摊派、强行分配等方式强制员工参与 员工持股计划的情形。 4、公司第 4 期员工持股计划拟定的持有人均符合《指导意见》及其他法律 法规及规范性文件规定的持有人条件，符合本持股计划规定的持有人范围，其作 为公司本持股计划持有人的主体资格合法、有效。 5、公司实施员工持股计划有利于建立和完善员工与股东的利益共享机制， 有利于进一步完善公司治理水平，提高员工的凝聚力和公司竞争力，充分调动员 工的积极性和创造性，吸引和保留优秀人才，实现公司可持续发展。 综上，监事会认为，公司实施第 4 期持股计划符合公司长远发展的需要，不 存在损害公司及全体股东利益的情形，同意公司实施本次员工持股计划。 安徽安科生物工程（集团）股份有限公司 监事会关于第 4 期员工持股计划相关事项的核查意见 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）监事会根据 《中华人民共和国公司法》《中华人民共和国证券法》《关于上市公司实施员工持 股计划试点的指导意见》（以下简称"《指导意见》"）、《深圳证券交易所上市公司 自律监管指引第 2 ...